AU Patent

AU2012332424A1 — Combination therapy of Hsp90 inhibitors with platinum-containing agents

Assigned to Synta Phamaceuticals Corp · Expires 2014-06-05 · 12y expired

What this patent protects

A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also…

USPTO Abstract

A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also provided is a method of treating a proliferative disorder such as cancer in a subject in need thereof, using the pharmaceutical combination described herein.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012332424A1
Jurisdiction
AU
Classification
—
Expires
2014-06-05
Drug substance claim
No
Drug product claim
No
Assignee
Synta Phamaceuticals Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.